BUSINESS

U.S. imposes steep pharmaceutical tariffs; some metals adjusted

PUBLISHED Apr 2, 2026, 6:56 AM ET

Read, Watch or Listen

Media Bias Meter

Sources: 5

Center 80%

Right 20%

Sources: 5

Washington — On April 2, the U.S. administration issued executive orders imposing up to 100% tariffs on certain branded pharmaceutical imports while altering duties on metals, requiring firms to onshore production and accept pricing commitments to avoid or reduce levies. The orders include reduced tariff rates for the EU, Switzerland, Japan, South Korea and the UK, offer a 20% cut for companies investing in U.S. facilities, and set negotiation windows and deadlines as officials seek to secure domestic manufacturing and pricing deals this month.

By Ayesha A. | JQJO News

Timeline of Events

One year ago: 'Liberation Day' tariffs announced in the Rose Garden.
Subsequent months: Tariff rates changed frequently, disrupting supply chains and markets.
Early 2026: Legal and policy adjustments followed Supreme Court developments affecting previous levies.
April 2, 2026: Executive orders impose up to 100% tariffs on certain pharmaceuticals, alter metals duties.
April 2026: Administration offers reduced rates for partners, onshoring incentives, and sets negotiation deadlines.

News Intelligence

The new tariffs could impact your wallet. Prescription drug costs may rise due to the 100% tariff on certain imports. However, if you work in metal industries, changes in duties could affect your job. Keep an eye on how these tariffs impact your healthcare and employment situation.

Media Bias

Articles Published:: 5
Right Leaning:: 1
Left Leaning:: 0
Neutral:: 4
Distribution:: Left 0%, Center 80%, Right 20%

Who Benefited

Domestic pharmaceutical manufacturers and the U.S. Treasury could benefit from increased onshoring, higher domestic investment, and additional tariff revenues if companies comply with production and pricing conditions.

Who Impacted

Foreign drugmakers that fail to secure pricing or onshoring agreements, U.S. consumers facing potential price increases, and global supply chains experiencing added volatility and planning difficulties suffered immediate downsides.